Business Description
NRX Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US6294441000
Share Class Description:
STU:B1Q: Ordinary SharesDescription
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -3.49 | |||||
Debt-to-Equity | -0.42 | |||||
Debt-to-EBITDA | -0.31 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36 | |||||
3-Year EPS without NRI Growth Rate | 37.6 | |||||
3-Year FCF Growth Rate | -62.8 | |||||
3-Year Book Growth Rate | 46.7 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.79 | |||||
9-Day RSI | 55.81 | |||||
14-Day RSI | 54.72 | |||||
6-1 Month Momentum % | 25.37 | |||||
12-1 Month Momentum % | -40.53 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.21 | |||||
Quick Ratio | 0.21 | |||||
Cash Ratio | 0.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.9 | |||||
Shareholder Yield % | -10.37 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -251.79 | |||||
ROIC % | -221.48 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -1.14 | |||||
EV-to-Forward-EBIT | -1.78 | |||||
EV-to-EBITDA | -1.14 | |||||
EV-to-Forward-Revenue | 5.41 | |||||
EV-to-FCF | -2 | |||||
Earnings Yield (Greenblatt) % | -87.72 | |||||
FCF Yield % | -62.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NRX Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -1.114 | ||
Beta | 0 | ||
Volatility % | 108.29 | ||
14-Day RSI | 54.72 | ||
14-Day ATR (€) | 0.328569 | ||
20-Day SMA (€) | 4.807 | ||
12-1 Month Momentum % | -40.53 | ||
52-Week Range (€) | 2.14 - 8.45 | ||
Shares Outstanding (Mil) | 9.57 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NRX Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NRX Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
NRX Pharmaceuticals Inc Frequently Asked Questions
What is NRX Pharmaceuticals Inc(STU:B1Q)'s stock price today?
The current price of STU:B1Q is €4.88. The 52 week high of STU:B1Q is €8.45 and 52 week low is €2.14.
When is next earnings date of NRX Pharmaceuticals Inc(STU:B1Q)?
The next earnings date of NRX Pharmaceuticals Inc(STU:B1Q) is 2024-11-13 Est..
Does NRX Pharmaceuticals Inc(STU:B1Q) pay dividends? If so, how much?
NRX Pharmaceuticals Inc(STU:B1Q) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |